Methods of treating anti-nmdar-associated neuropsychiatric disorders
AssigneeVanderbilt University
InventorJill M. Pulley
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed to methods for treating a neuropsychiatric disorder associated with expression of autoantibodies to ionotropic glutamate receptor, NMD A 2A (GiuN2A), expression of anti-double-stranded (ds) DNA antibodies that cross react with one or more subunits of the NMD A receptor, or a mutation in the ionotropic glutamate receptor NMD A type subunit 2A (GRIN2A) gene. The methods involve administering a memantine, or a pharmaceutically acceptable salt thereof, to a subject suffering from a neuropsychiatric disorder associated with expression of GluN2A or a mutation in the GRIN2A gene.
Claims17
A method of treating a neuropsychiatric disorder in a subject comprising administering a therapeutically effective amount of memantine, or a pharmaceutically acceptable salt thereof, to the subject, wherein the subject has a mutation in the ionotropic glutamate receptor NMDA type subunit 2A (GRIN2A) gene.
A method of treating a neuropsychiatric disorder in a subject comprising administering a therapeutically effective amount of memantine, or a pharmaceutically acceptable salt thereof, to the subject, wherein the subject expresses autoantibodies to ionotropic glutamate receptor, NMDA 2A (GluN2A) and/or anti-double-stranded (ds) DNA antibodies that cross react with one or more subunits of the NMDA receptor.
A method of treating a neuropsychiatric disorder associated with expression of autoantibodies to ionotropic glutamate receptor, NMDA 2A (GluN2A) in a subject in need of treatment, the method comprising administering to the subject a therapeutically effective amount of memantine or a pharmaceutically acceptable salt thereof.
A method of treating a neuropsychiatric disorder in a subject in need of treatment, the method comprising administering to the subject a therapeutically effective amount of memantine or a pharmaceutically acceptable salt thereof after autoantibodies to ionotropic glutamate receptor, NMDA 2A (GluN2A) and/or anti-double-stranded (ds) DNA antibodies that cross react with one or more subunits of the NMDA receptor are detected in the subject.
Dependencies are inferred from the claim text.